6 rue Alain Bombard
33 2 28 07 37 10
Full Time Employees: 719
|Mr. Thomas Lingelbach||Chairman of the Management Board, Pres & CEO||783.68k||N/A||1963|
|Mr. Peter Buhler||CFO & Management Board Member||519.98k||N/A||1971|
|Mr. Franck Grimaud MBA||Director Gen., Chief Bus. Officer & Member of Management Board||389.29k||N/A||1967|
|Mr. Frederic Jacotot||VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board||298.48k||N/A||1965|
|Dr. Juan-Carlos Jaramillo M.D.||Chief Medical Officer & Member of the Management Board||472.53k||N/A||1972|
|Ms. Dipal Patel||Chief Commercial Officer & Member of Management Board||759.39k||N/A||1974|
|Mr. Perry Celentano||Interim Chief Operating Officer||N/A||N/A||N/A|
|Mr. Joshua Drumm Ph.D.||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Laetitia Bachelot-Fontaine||VP of Global Communications & European Investor Relations||N/A||N/A||N/A|
|Mr. Gerald Strohmaier||VP of Human Resource||N/A||N/A||N/A|
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Valneva SE’s ISS Governance QualityScore as of May 1, 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 6; Compensation: 10.